Connor, Clark & Lunn Investment Management (CC&L)
CTMX icon

Connor, Clark & Lunn Investment Management (CC&L)’s CytomX Therapeutics CTMX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-286,480
Closed -$295K – 1447
2024
Q4 		$295K Buy
286,480
+5,887
+2% +$6.33K ﹤0.01% 1261
2024
Q3 		$331K Buy
280,593
+26,373
+10% +$33.5K ﹤0.01% 1207
2024
Q2 		$310K Sell
254,220
-50,114
-16% -$99.8K ﹤0.01% 1177
2024
Q1 		$663K Buy
304,334
+107,814
+55% +$199K ﹤0.01% 1025
2023
Q4 		$305K Buy
196,520
+50,586
+35% +$66.5K ﹤0.01% 1170
2023
Q3 		$188K Sell
145,934
-10,106
-6% -$15.9K ﹤0.01% 1245
2023
Q2 		$268K Buy
156,040
+21,731
+16% +$36.1K ﹤0.01% 1131
2023
Q1 		$203K Sell
134,309
-16,711
-11% -$37.8K ﹤0.01% 1095
2022
Q4 		$242K Sell
151,020
-59,679
-28% -$88.3K ﹤0.01% 1019
2022
Q3 		$306K Buy
210,699
+3,628
+2% +$5.58K ﹤0.01% 917
2022
Q2 		$379K Buy
207,071
+6,872
+3% +$13.2K ﹤0.01% 832
2022
Q1 		$535K Sell
200,199
-1,559
-0.8% -$5.99K ﹤0.01% 775
2021
Q4 		$874K Buy
201,758
+146,813
+267% +$860K ﹤0.01% 702
2021
Q3 		$280K Buy
+54,945
New +$294K ﹤0.01% 888
2021
Q2 		– Sell
-92,243
Closed -$713K – 996
2021
Q1 		$713K Buy
92,243
+33,764
+58% +$267K ﹤0.01% 744
2020
Q4 		$383K Buy
58,479
+35,092
+150% +$251K ﹤0.01% 758
2020
Q3 		$156K Sell
23,387
-24,167
-51% -$179K ﹤0.01% 858
2020
Q2 		$396K Sell
47,554
-51,894
-52% -$482K ﹤0.01% 793
2020
Q1 		$763K Buy
99,448
+68,673
+223% +$479K 0.01% 616
2019
Q4 		$256K Buy
+30,775
New +$208K ﹤0.01% 791
2017
Q3 		– Sell
-14,450
Closed -$224K – 830
2017
Q2 		$224K Buy
+14,450
New +$218K ﹤0.01% 720

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CTMX Position: Q1 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of CytomX Therapeutics (CTMX) in Q1 2025, closing a stake of 286,480 shares — an estimated $295K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CTMX in Q2 2017 and held it in 21 quarters. The position peaked at $874K in Q4 2021. 66 funds tracked by Wall St. Rank hold CTMX as of Q1 2025.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining CytomX Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 286,480 CytomX Therapeutics shares in Q1 2025, an estimated $295K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CytomX Therapeutics in Q2 2017 and held it in 21 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s CytomX Therapeutics position peaked at $874K in Q4 2021.
  • 66 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2025, filed 12 May 2025.